RESUMO
OBJECTIVES: Hydroxychloroquine (HCQ) is a key therapy in systemic lupus erythematosus (SLE). Medication non-adherence is reported in up to 80% of lupus patients and results in increased morbidity, mortality, and health care utilization. HCQ levels are a sensitive and reliable method to assess medication adherence. Our study evaluated the role of HCQ level measurement in routine clinical care and its association with disease activity in a predominantly Hispanic population. METHODS: SLE patients from the Columbia University Lupus cohort treated with HCQ for ≥ 6 months and reporting medication adherence were included. HCQ levels were measured by whole blood high performance liquid chromatography. Non-adherence was defined as an HCQ level <500 ng/ml. The association between HCQ levels and disease activity measured by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) was evaluated. RESULTS: One hundred and eight patients were enrolled; the median age was 38 years, 91% were female, and 63% were Hispanic. The median SLEDAI-2K was 4.3 (0-20). Forty-one percent of patients had an HCQ level <500 ng/ml consistent with non-adherence, of which 19% had undetectable levels. A higher SLEDAI-2K score was associated with low HCQ levels (p = 0.003). This association remained significant after adjusting for depression (p = 0.0007). CONCLUSION: HCQ levels < 500 ng/ml were associated with higher disease activity and accounted for 32% of the SLEDAI-2K variability. HCQ blood measurement is a simple and reliable method to evaluate medication adherence in SLE. Reasons for non-adherence (levels < 500 ng/ml) should be further explored and addressed.
Assuntos
Antirreumáticos/sangue , Hidroxicloroquina/sangue , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Adesão à Medicação , Adulto , Idoso , Antirreumáticos/uso terapêutico , Cromatografia Líquida de Alta Pressão , Estudos de Coortes , Esquema de Medicação , Monitoramento de Medicamentos , Feminino , Hispânico ou Latino , Humanos , Hidroxicloroquina/uso terapêutico , Modelos Lineares , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/etnologia , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Resultado do Tratamento , Estados Unidos , Adulto JovemRESUMO
OBJECTIVE: Elevated levels of cell-bound complement activation products (CB-CAPs) (C4d deposition on B lymphocytes (BC4d) and/or erythrocytes (EC4d)) are sensitive and specific in diagnosis and monitoring of adult systemic lupus erythematosus (SLE). Our objective was to evaluate the role of CB-CAPs for diagnosis and monitoring of pediatric-onset SLE (pSLE). METHODS: A prospective cohort study of 28 pSLE and 22 juvenile arthritis patients was conducted. SLE disease activity was determined using a clinical Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) that excluded serologies. Autoantibodies were measured using solid-phase immunoassays, C3 and C4 using immunoturbidimetry, and CB-CAPs using quantitative flow cytometry. Abnormal CB-CAPs were defined as EC4d or BC4d above the 99th percentile for healthy adults (>14 and > 60 net mean fluorescence intensity (MFI), respectively). Performance characteristics of CB-CAPs were assessed using area under the curve (AUC) for receiver operating characteristics. Linear mixed effect models evaluated the correlation between CB-CAPs and clinical SLEDAI over 6 months. RESULTS: BC4d yielded higher AUC (0.91 ± 0.04) than C3 (0.63 ± 0.08) and C4 (0.67 ± 0.08) ( p < 0.05). Abnormal CB-CAPs were 78% sensitive and 86% specific for diagnosis of pSLE (Youden's index = 0.64 ± 0.11). In contrast to BC4d, EC4d levels correlated with clinical SLEDAI ( p < 0.01). CONCLUSION: CB-CAPs (EC4d and BC4d) have higher sensitivity and specificity than low complement in pSLE, and may help with diagnosis of pSLE. EC4d could provide a useful biomarker for disease activity monitoring.
Assuntos
Autoanticorpos/sangue , Biomarcadores/metabolismo , Proteínas do Sistema Complemento/metabolismo , Lúpus Eritematoso Sistêmico/diagnóstico , Adolescente , Idade de Início , Ativação do Complemento , Feminino , Citometria de Fluxo , Humanos , Imunoensaio , Lúpus Eritematoso Sistêmico/imunologia , Masculino , Estudos Prospectivos , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Adulto JovemAssuntos
Autoanticorpos/sangue , Doenças Autoimunes , Carbamilação de Proteínas/imunologia , Doenças Reumáticas , Doenças Autoimunes/sangue , Doenças Autoimunes/diagnóstico , Diagnóstico Diferencial , Ensaio de Imunoadsorção Enzimática/métodos , Humanos , Doenças Reumáticas/sangue , Doenças Reumáticas/diagnósticoRESUMO
Pharmacogenetics is the study of how genetic variations affect drug response. These variations can affect a patient's response to cancer drugs, for which there is usually a fine line between a dosage that has a therapeutic effect and one that produces toxicity. Gaining better insight into the genetic elements of both the patient and the tumour that affect drug efficacy will eventually allow for individualized dosage determination and fewer adverse effects.
Assuntos
Neoplasias/tratamento farmacológico , Farmacogenética , Transportadores de Cassetes de Ligação de ATP/genética , Antimetabólitos Antineoplásicos/farmacocinética , Antineoplásicos/efeitos adversos , Antineoplásicos/classificação , Antineoplásicos/farmacocinética , Biotransformação/genética , Sistema Enzimático do Citocromo P-450/genética , Inibidores Enzimáticos/farmacocinética , Antagonistas do Ácido Fólico/farmacocinética , Previsões , Predisposição Genética para Doença , Variação Genética , Genótipo , Humanos , Hipoxantina Fosforribosiltransferase/genética , Metiltransferases/genética , Neoplasias/genética , Polimorfismo de Nucleotídeo Único , Receptores de Droga/genética , Transferases/genéticaRESUMO
Thioguanine and mercaptopurine are prodrugs requiring conversion into thiopurine nucleotides to exert cytotoxicity. Thiopurine S-methyltransferase (TPMT), an enzyme subject to genetic polymorphism, catabolizes thiopurines into inactive methylated bases, but also produces methylthioguanine nucleotides and methylmercaptopurine nucleotides from thioguanine and mercaptopurine nucleotides, respectively. To study the effect of TPMT on activation versus inactivation of mercaptopurine and thioguanine, we used a retroviral gene transfer technique to develop human CCRF-CEM cell lines that did (TPMT+) and did not (MOCK) overexpress TPMT. After transduction, TPMT activities were 14-fold higher in the TPMT+ versus the MOCK cell lines (P < 0.001). TPMT+ cells were less sensitive to thioguanine than MOCK cells (IC(50) = 1.10+/- 0.12 microM versus 0.55 +/- 0.19 microM; P = 0.02); in contrast, TPMT+ cells were more sensitive to mercaptopurine than MOCK cells (IC(50) = 0.52 +/- 0.20 microM versus 1.50 +/- 0.23 microM; P < 0.01). The lower sensitivity of TPMT+ versus MOCK cells to thioguanine was associated with lower thioguanine nucleotide concentrations (917 +/- 282 versus 1515 +/- 183 pmol/5 x 10(6) cells; P = 0.01), higher methylthioguanine nucleotide concentrations (252 +/- 34 versus 27 +/- 10 pmol/5 x 10(6) cells; P = 0.01), less inhibition of de novo purine synthesis (13 versus 95%; P < 0.01), and lower deoxythioguanosine incorporation into DNA (2.0 +/- 0.6% versus 7.2 +/- 2.0%; P < 0.001). The higher sensitivity of TPMT+ cells to mercaptopurine was associated with higher concentrations of methylmercaptopurine nucleotide (2601 +/- 1055 versus 174 +/- 77 pmol/5 x 10(6) cells; P = 0.01) and greater inhibition of de novo purine synthesis (>99% versus 74%; P < 0.01) compared with MOCK cells. We conclude that methylation of mercaptopurine contributes to the antiproliferative properties of the drug, probably through inhibition of de novo purine synthesis by methylmercaptopurine nucleotides, whereas thioguanine is inactivated primarily by TPMT.
Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Leucemia-Linfoma de Células T do Adulto/tratamento farmacológico , Leucemia-Linfoma de Células T do Adulto/enzimologia , Mercaptopurina/análogos & derivados , Mercaptopurina/farmacologia , Metiltransferases/metabolismo , Tioguanina/farmacologia , Células 3T3 , Animais , Antimetabólitos Antineoplásicos/farmacocinética , Biotransformação , Citosol/metabolismo , DNA de Neoplasias/metabolismo , Desoxiguanosina/metabolismo , Técnicas de Transferência de Genes , Células HeLa , Humanos , Leucemia-Linfoma de Células T do Adulto/genética , Mercaptopurina/farmacocinética , Metiltransferases/biossíntese , Metiltransferases/genética , Camundongos , Nucleotídeos de Purina/metabolismo , Purinas/biossíntese , Retroviridae/genética , Tioguanina/farmacocinética , Tionucleosídeos/metabolismo , Tionucleotídeos/metabolismo , Células Tumorais CultivadasRESUMO
Methotrexate is widely administered with mercaptopurine, a prodrug requiring activation into thioguanine nucleotides (TGN) to exert antileukemic effects. In vitro, methotrexate enhances TGN formation, but in vivo, such enhancement has yet to be demonstrated. We investigated whether TGN concentrations were related to methotrexate concentrations in children with acute lymphoblastic leukemia who received a weekly intravenous methotrexate (40 mg/m(2)) dose combined with daily mercaptopurine (75 mg/m(2)). A total of 141 erythrocyte TGN concentrations were measured with erythrocyte methotrexate polyglutamates (MTX-PG) concentrations in 87 patients. Average TGN concentrations ranged from 137 to 958 pmol/8 x 10(8) cells (median 389), average total MTX-PG concentrations (MTX- PG(1-7)) from 0.60 to 97.7 pmol/10(9)cells (median 29), and average long chain polyglutamate concentrations (MTX-PG(5-7)) from 0 to 8.35 pmol/10(9) cells (median 2.43). Higher TGN concentrations correlated with higher MTX-PG(5-7) concentrations (P = 0.002). These data support the practice of administering methotrexate with mercaptopurine during continuation therapy of acute lymphoblastic leukemia.
Assuntos
Antimetabólitos Antineoplásicos/farmacocinética , Inosina Monofosfato/análogos & derivados , Mercaptopurina/farmacocinética , Metotrexato/análogos & derivados , Metotrexato/sangue , Metotrexato/farmacologia , Ácido Poliglutâmico/análogos & derivados , Ácido Poliglutâmico/sangue , Pró-Fármacos/farmacocinética , Algoritmos , Antimetabólitos Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biotransformação/efeitos dos fármacos , Criança , Esquema de Medicação , Eritrócitos/química , Humanos , Hipoxantina Fosforribosiltransferase/metabolismo , Inativação Metabólica , Injeções Intravenosas , Inosina Monofosfato/biossíntese , Inosina Monofosfato/sangue , Mercaptopurina/administração & dosagem , Metotrexato/administração & dosagem , Metiltransferases/metabolismo , Proteínas de Neoplasias/metabolismo , Nucleotídeos/biossíntese , Nucleotídeos/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Pró-Fármacos/administração & dosagem , Tioguanina/sangue , Tionucleotídeos/biossíntese , Tionucleotídeos/sangue , Xantina Oxidase/metabolismoRESUMO
6-Mercaptopurine (6-MP) is metabolized by thiopurine S-methyltransferase (TPMT), an enzyme subject to genetic polymorphism. We investigated the relationships between the TPMT locus (TPMT activity and genotype) and the pharmacological response to 6-MP during maintenance therapy of 78 children with acute lymphoblastic leukemia (ALL). For each patient, 6-MP dosage, leukocyte counts and occurrence of infectious episodes were monitored on an 8 week basis. Higher 6-MP dosage was associated with higher TPMT activity (P = 0.03) and higher average leukocyte counts (P < 0.01). Eight patients (10%) carrying a TPMT mutant genotype (one homozygous and seven heterozygous) received lower 6-MP doses (average: 48 vs 65 mg/m2/day; P = 0.02) and had on average lower leukocyte counts (2834 vs 3398 cells/mm3; P = 0.003) than patients carrying the wild-type TPMT genotype. Higher occurrence of infectious episodes graded 2 or 3 was correlated with higher 6-MP dosage (P < 0.01) but no difference was observed between TPMT mutants and TPMT wild-type patients. Patients who received 6-MP dosage above the group median (62 mg/m2/day) or having a TPMT activity above the group median (21.5 nmol/h/ml) had a higher percentage of 8 week periods with infectious episodes requiring treatment (34% vs 17% and 33% vs 19%, respectively) than those with 6-MP dose or TPMT activity below the group median (P < 0.01). In the last 25 patients enrolled in the study, steady-state erythrocyte thioguanine nucleotide (TGN) concentrations were associated with lower leukocyte counts (P= 0.01) but not with a higher occurrence of infectious episodes. In contrast, higher steady-state erythrocyte methylmercaptopurine nucleotide (MeMPN) concentrations were associated with higher 6-MP dosage (P< 0.01) and higher occurrence of infectious episodes (P < 0.001). In conclusion, during maintenance therapy of ALL, children with higher TPMT activity receive a higher 6-MP dosage and may have infectious episodes caused by metabolism of 6-MP into methylmercaptopurine nucleotides.
Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Infecções/etiologia , Mercaptopurina/análogos & derivados , Mercaptopurina/efeitos adversos , Metiltransferases/fisiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Adolescente , Antimetabólitos Antineoplásicos/administração & dosagem , Antimetabólitos Antineoplásicos/farmacocinética , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Eritrócitos/metabolismo , Feminino , Genótipo , Humanos , Lactente , Contagem de Leucócitos , Masculino , Mercaptopurina/administração & dosagem , Mercaptopurina/metabolismo , Mercaptopurina/farmacocinética , Metiltransferases/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevenção & controle , Tioguanina/metabolismoRESUMO
PURPOSE: Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) and lymphoblasts. METHODS: To clarify the pharmacokinetic interactions between these two antimetabolites, we serially measured RBC 6-TGN and MTX polyglutamates (MTXPG) levels following repeated courses of HDMTX (5 g/m(2) over 24 h) with daily oral 6-MP (25 mg/m(2)) during interval therapy in 20 children with ALL. RESULTS: HDMTX produced a rapid reduction in RBC 6-TGN 24 h after the start of MTX, and this effect was sustained at least by the third day (median decrease -21%; P < 0.001). However, a return to pre-infusion of 6-TGN levels was observed by the time of the following HDMTX course 14 days later (P < 0.001). RBC MTX polyglutamates accumulation followed Michaelis-Menten kinetics but was not associated with the change in pre-infusion 6-TGN levels which remained stable during the interval period. CONCLUSION: HDMTX does not appear to enhance 6-MP activation to 6-TGN. Moreover, given that the deleterious effect of HDMTX on intracellular 6-MP disposition has been shown to be several folds greater in lymphoblasts than in RBC. Our data warrant additional studies elucidating the optimal MTX dose synergizing with 6-MP.
Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Antimetabólitos Antineoplásicos/farmacocinética , Mercaptopurina/farmacocinética , Metotrexato/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Adolescente , Antimetabólitos Antineoplásicos/uso terapêutico , Biotransformação , Criança , Pré-Escolar , Interações Medicamentosas , Eritrócitos/metabolismo , Feminino , Humanos , Inativação Metabólica/fisiologia , Injeções Intravenosas , Masculino , Mercaptopurina/administração & dosagem , Mercaptopurina/uso terapêutico , Metotrexato/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Tioguanina/metabolismoAssuntos
Azatioprina/uso terapêutico , Eritrócitos/enzimologia , Imunossupressores/uso terapêutico , Transplante de Rim/fisiologia , Metiltransferases/sangue , Corticosteroides/uso terapêutico , Criança , Ciclosporina/uso terapêutico , Monitoramento de Medicamentos/métodos , Quimioterapia Combinada , Feminino , Rejeição de Enxerto/sangue , Rejeição de Enxerto/enzimologia , Humanos , Transplante de Rim/imunologia , MasculinoAssuntos
Eritrócitos/química , Mercaptopurina/sangue , Tioguanina/sangue , Azatioprina/uso terapêutico , Cromatografia Líquida de Alta Pressão/métodos , Monitoramento de Medicamentos/métodos , Transplante de Coração-Pulmão/imunologia , Transplante de Coração-Pulmão/fisiologia , Humanos , Hidrólise , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeAssuntos
Azatioprina/uso terapêutico , Metilação de DNA , Nucleotídeos de Guanina/metabolismo , Transplante de Coração-Pulmão , Imunossupressores/uso terapêutico , Mercaptopurina/metabolismo , Tionucleotídeos/metabolismo , Adulto , Relação Dose-Resposta a Droga , Eritrócitos/metabolismo , Feminino , Humanos , Masculino , Metiltransferases/metabolismo , Pessoa de Meia-Idade , Monitorização FisiológicaRESUMO
The influence of genetic polymorphism in inosine triphosphate pyrophosphatase (ITPA) on thiopurine-induced adverse events has not been investigated in the context of combination chemotherapy for acute lymphoblastic leukemia (ALL). This study investigated the effects of a common ITPA variant allele (rs41320251) on mercaptopurine metabolism and toxicity during treatment of children with ALL. Significantly higher concentrations of methyl mercaptopurine nucleotides were found in patients with the nonfunctional ITPA allele. Moreover, there was a significantly higher probability of severe febrile neutropenia in patients with a variant ITPA allele among patients whose dose of mercaptopurine had been adjusted for TPMT genotype. In a cohort of patients whose mercaptopurine dose was not adjusted for TPMT phenotype, the TPMT genotype had a greater effect than the ITPA genotype. In conclusion, genetic polymorphism of ITPA is a significant determinant of mercaptopurine metabolism and of severe febrile neutropenia, after combination chemotherapy for ALL in which mercaptopurine doses are individualized on the basis of TPMT genotype.
Assuntos
Mercaptopurina/efeitos adversos , Mercaptopurina/metabolismo , Polimorfismo Genético/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/enzimologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Pirofosfatases/genética , Adolescente , Criança , Pré-Escolar , Feminino , Gastroenteropatias/induzido quimicamente , Gastroenteropatias/enzimologia , Gastroenteropatias/genética , Humanos , Lactente , Masculino , Neutropenia/induzido quimicamente , Neutropenia/enzimologia , Neutropenia/genética , Polimorfismo Genético/efeitos dos fármacos , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Pirofosfatases/metabolismoRESUMO
OBJECTIVE: To investigate the contribution of red blood cell (RBC) methotrexate polyglutamates (MTX PGs), RBC folate polyglutamates (folate PGs), and a pharmacogenetic index to the clinical status of patients with rheumatoid arthritis treated with MTX. METHODS: 226 adult patients treated with weekly MTX for more than 3 months were enrolled at three sites in a multicentred cross sectional observational study. Clinical status was assessed by the number of joint counts, physician's global assessment of disease activity, and a modified Health Assessment Questionnaire (mHAQ). RBC MTX PG and folate PG metabolite levels were measured by high performance liquid chromatography fluorometry and radioassay, respectively. A composite pharmacogenetic index comprising low penetrance genetic polymorphisms in reduced folate carrier (RFC-1 G80A), AICAR transformylase (ATIC C347G), and thymidylate synthase (TSER*2/*3) was calculated. Statistical analyses were by multivariate linear regression with clinical measures as dependent variables and metabolite levels and the pharmacogenetic index as independent variables after adjustment for other covariates. RESULTS: Multivariate analysis showed that lower RBC MTX PG levels (median 40 nmol/l) and a lower pharmacogenetic index (median 2) were associated with a higher number of joint counts, higher disease activity, and higher mHAQ (p<0.09). Multivariate analysis also established that higher RBC folate PG levels (median 1062 nmol/l) were associated with a higher number of tender and swollen joints after adjustment for RBC MTX PG levels and the pharmacogenetic index (p<0.05). CONCLUSION: Pharmacogenetic and metabolite measurements may be useful in optimising MTX treatment. Prospective studies are warranted to investigate the predictive value of these markers for MTX efficacy.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/genética , Metotrexato/uso terapêutico , Idoso , Artrite Reumatoide/sangue , Biomarcadores/sangue , Estudos Transversais , Eritrócitos/metabolismo , Feminino , Humanos , Hidroximetil e Formil Transferases/genética , Modelos Lineares , Masculino , Proteínas de Membrana Transportadoras/genética , Metotrexato/análogos & derivados , Metotrexato/sangue , Pessoa de Meia-Idade , Fosforribosilaminoimidazolcarboxamida Formiltransferase , Ácido Poliglutâmico/análogos & derivados , Ácido Poliglutâmico/sangue , Ácidos Pteroilpoliglutâmicos/sangue , Proteína Carregadora de Folato Reduzido , Índice de Gravidade de Doença , Timidilato Sintase/genéticaRESUMO
6-thioguanine (6-TGN) and methyl 6-mercaptopurine nucleotides (Me6-MPNs) are the two major metabolites found in erythrocytes after administration of azathioprine. In an attempt to understand the role of these metabolites in the pharmacologic and toxic activity of thiopurines, we have developed a HPLC method for the simultaneous determination of 6-TGNs and Me6-MPNs in erythrocytes. A simple and rapid treatment procedure based on deproteinization by perchloric acid with dithiothreitol is described. The nucleotides were hydrolyzed to their own bases by heating the sample for 45 min at 100 degrees C. During acid hydrolysis Me6-MP was converted into a compound analyzed on a Purospher RP18-e column with 0.02 mol/L dihydrogenophosphate buffer-methanol as eluents. With this procedure, mean recoveries of 73.1% and 84.0% for 6-TGN and Me6-MPN derivatives, respectively, were found.
Assuntos
Azatioprina/farmacocinética , Eritrócitos/química , Mercaptopurina/sangue , Nucleotídeos/sangue , Tioguanina/sangue , Azatioprina/sangue , Azatioprina/uso terapêutico , Biotransformação , Cromatografia Líquida de Alta Pressão/métodos , Eritrócitos/metabolismo , Transplante de Coração-Pulmão/imunologia , Humanos , Hidrólise , Imunossupressores/farmacocinética , Imunossupressores/uso terapêutico , Indicadores e Reagentes , Transplante de Pulmão/imunologia , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
6-Thioguanine and 6-methylmercaptopurine (Me6-MP) nucleotides are the two major thiopurine metabolites of azathioprine found in erythrocytes. During the acid hydrolysis required for the conversion of thiopurine nucleotides into their free bases, Me6-MP was converted into a compound that could be analyzed on a Purospher RP18-e column with dihydrogen phosphate-methanol buffer as eluent. The pH of the acid extract strongly influenced the conversion of Me6-MP into its derivative. The Me6-MP derivative was identified using liquid chromatography-mass spectrometry and infrared and nuclear magnetic resonance spectrometric methods. During the acid hydrolysis of thiopurine nucleotides in erythrocytes, Me6-MP undergoes degradation, leading to 4-amino-5-(methylthio)carbonyl imidazole.
Assuntos
Eritrócitos/química , Imidazóis/sangue , Mercaptopurina/análogos & derivados , Tionucleotídeos/química , Azatioprina/sangue , Cromatografia Líquida , Humanos , Hidrólise , Imunossupressores/sangue , Técnicas In Vitro , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Mercaptopurina/sangue , Percloratos , Espectrofotometria InfravermelhoRESUMO
AIMS: Azathioprine is a prodrug commonly used in combination therapy to prevent allograft rejection after renal transplantation. After conversion to 6-mercaptopurine, the drug is metabolized into 6-thioguanine nucleotides (6-TGN) and catabolized by thiopurine methyltransferase (TPMT), an enzyme under monogenic control. The aim of this study was to evaluate the inter- and intraindividual variability of red blood cell thiopurine methyltransferase and 6-TGN concentrations and their relationship to the clinical effects of azathioprine in paediatric patients. METHODS: In the present study, the inter- and intraindividual variations in red blood cell TPMT activity and 6-TGN concentrations and their relationship to the actions of azathioprine were evaluated during the first year after renal transplantation in 22 paediatric patients. RESULTS: 6-TGN concentration reached steady-state values after 6 months and correlated negatively with TPMT activity (P=0.004). Initial TPMT activity (median: 20.8 nmol h-1 ml-1, range 7.8-34.6) and 6-TGN concentration at steady-state (median: 80 pmol 8 x 10(8-1) cells, range not detected to 366) were not related to the occurrence of rejection episodes during the period of the study. In contrast, TPMT activity and the percentage difference in TPMT activity from the day of transplantation determined at month 1 were higher in the patients with rejection episodes by comparison with those that did not reject during the first 3 months or the first year following transplantation (P<0.005). CONCLUSIONS: We report a relationship between TPMT activity and occurrence of rejection in paediatric kidney transplant patients undergoing azathioprine therapy. These data suggest a link between high red blood cell TPMT activity and poor clinical outcome probably caused by rapid azathioprine catabolism.
Assuntos
Antimetabólitos/farmacologia , Azatioprina/farmacologia , Rejeição de Enxerto/metabolismo , Imunossupressores/farmacologia , Transplante de Rim , Metiltransferases/metabolismo , Pró-Fármacos/farmacologia , Criança , Cromatografia Líquida de Alta Pressão , Feminino , Genótipo , Nucleotídeos de Guanina/sangue , Nucleotídeos de Guanina/metabolismo , Humanos , Transplante de Rim/fisiologia , Masculino , Metiltransferases/sangue , Metiltransferases/genética , Tionucleotídeos/sangue , Tionucleotídeos/metabolismoRESUMO
Therapy-related acute myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a child who developed t-AML with a t(11;19) (q23;p13.3) during treatment for acute lymphoblastic leukemia (ALL). The MLL-ENL and the reciprocal ENL-MLL genomic fusions and their chimeric transcripts were characterized from samples collected at the time of t-AML diagnosis. We used PCR with patient-specific genomic primers to establish the emergence of the MLL-ENL fusion in serially obtained DNA samples. The MLL-ENL fusion was not detectable in bone marrow at the time of ALL diagnosis or after 2 months of chemotherapy (frequency <8.3 x 10(-7) cells(-1)). The genomic fusion was first detected in bone marrow after 6 months of treatment at a frequency of one in 4,000 mononuclear bone marrow cells; the frequency was one in 70 cells after 20 months of therapy. At the first detection of MLL-ENL, the only topoisomerase II inhibitors the patient had received were one dose of daunorubicin and two doses of etoposide. The MLL-ENL fusion was not detectable in blood at the time of ALL diagnosis or after 0.7, 2, 8, 10, and 12 months of therapy but was detectable in blood at 16 months (one in 2.3 x 10(4) cells). Recombinogenic Alu sequences bracketed the breakpoints in both fusions. These data indicate that the malignant clone was not present before therapy, arose early during chemotherapy, and was able to proliferate even during exposure to antileukemic therapy.